04 May 2009 - GlaxoSmithKline update: influenza A (H1N1) "GSK has increased production levels for Relenza and is now set to produce between 50-60 million treatment packs of Relenza per year. Part of this production is from our Melbourne site in Australia. The company expects to achieve this rate of output (5 million treatment packs per month) within the next 12 to 14 weeks."
23rd July 2009 "The plans include a commitment by GSK to increase its annual production capacity of the influenza anti-viral Relenza to 190 million courses by the end of 2009. This increase represents a threefold increase to GSK’s previous capacity of 60 million courses."
Production and presumably sales are therefore
July <4 – <5M/m Aug 4 - 5M/m Sep >4 - >5M/m
So minimum production is around 12m and maximum between 15 and say 18m.
Two million are to be donated to WHO, etc. with no royalty going to BTA. The timing of the donation is unknown.
In part offset by higher royalties of 10% from Australian and NZ sales.
Also, as noted from ?Taiwan, there are few govt discounts available as demand is well in excess of supply.
Foreign currency variations confuse the picture.
M
BTA Price at posting:
$2.93 Sentiment: Buy Disclosure: Held
